share_log

Ardelyx | 8-K: Current report

Ardelyx | 8-K: Current report

Ardelyx | 8-K：重大事件
美股sec公告 ·  06/17 09:05
Moomoo AI 已提取核心訊息
Ardelyx, Inc., a biopharmaceutical company, announced the approval of amendments and restatements to its equity and employee stock plans following its 2024 Annual Meeting of Stockholders on June 14, 2024. The Board of Directors initially approved the changes to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan on April 29, 2024. These amendments, referred to as the A&R 2014 Equity Plan and the A&R ESPP respectively, were subsequently ratified by stockholders at the Annual Meeting. The meeting also saw the election of Class I director nominees, approval of executive compensation on an advisory basis, and ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The detailed proposals and voting outcomes are incorporated by reference from the Proxy Statement filed with the SEC on April 29, 2024, and supplemented on June 4, 2024.
Ardelyx, Inc., a biopharmaceutical company, announced the approval of amendments and restatements to its equity and employee stock plans following its 2024 Annual Meeting of Stockholders on June 14, 2024. The Board of Directors initially approved the changes to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan on April 29, 2024. These amendments, referred to as the A&R 2014 Equity Plan and the A&R ESPP respectively, were subsequently ratified by stockholders at the Annual Meeting. The meeting also saw the election of Class I director nominees, approval of executive compensation on an advisory basis, and ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The detailed proposals and voting outcomes are incorporated by reference from the Proxy Statement filed with the SEC on April 29, 2024, and supplemented on June 4, 2024.
生物製藥公司Ardelyx，Inc.宣佈，在2024年6月14日股東年度大會後，其股權和員工股票計劃獲得修正和重新制定的批准。董事會最初於2024年4月29日批准了《2014年股權激勵獎勵計劃》和《2014年員工股票購買計劃》的這些更改。這些修正案分別被股東在年度股東大會上批准，分別稱爲《修訂後2014年股權計劃》和《修訂後ESPP》。會議還看到了I級董事候選人的選舉、對高管薪酬的建議性批准和Ernst & Young LLP作爲截至2024年12月31日的獨立註冊公共會計師事務所的批准。詳細的提案和投票結果是從2024年4月29日提交給美國證券交易委員會的代理聲明中引入並於2024年6月4日進行補充。
生物製藥公司Ardelyx，Inc.宣佈，在2024年6月14日股東年度大會後，其股權和員工股票計劃獲得修正和重新制定的批准。董事會最初於2024年4月29日批准了《2014年股權激勵獎勵計劃》和《2014年員工股票購買計劃》的這些更改。這些修正案分別被股東在年度股東大會上批准，分別稱爲《修訂後2014年股權計劃》和《修訂後ESPP》。會議還看到了I級董事候選人的選舉、對高管薪酬的建議性批准和Ernst & Young LLP作爲截至2024年12月31日的獨立註冊公共會計師事務所的批准。詳細的提案和投票結果是從2024年4月29日提交給美國證券交易委員會的代理聲明中引入並於2024年6月4日進行補充。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息